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ABSTRACT Interferons regulate the expression of a large
number of mammalian genes, including the major histocom-
patibility antigen genes. To investigate the mechanisms in-
volved in interferon action, we have analyzed the ability of
murine H-2Ld and H-2Dd DNA sequences to control the
responses to interferon. The results indicate that interferon
regulation of class I gene expression is complex and involves at
least two mechanisms that are dependent on class I sequences
located upstream and downstream to the transcription initia-
tion site. In transfected mouse L cells, both of these regions are
required for full enhancement of class I gene expression, with
the major portion of the response controlled by the sequences
located 3' to the transcription initiation site. The fine-mapping
analysis of the 5' region-encoded response also suggests that
recombinant a and y interferons may exert their effects on
class I gene expression by using different cis-acting regulatory
sequences.
Transplantation antigens are membrane-bound glycoproteins
that function as recognition molecules for cytotoxic T lym-
phocytes during graft rejection and immune elimination of
cells expressing foreign antigens (1, 2). They consist of an
-45-kDa heavy chain (class I protein) noncovalently asso-
ciated with a 12-kDa light chain [,32-microglobulin (f32m)] (3).
Class I proteins are highly polymorphic and are encoded
within the major histocompatibility complex by the H-2K,
H-2D, and H-2L loci in the mouse (4). Although they are
found on most somatic cells of the body, their expression
level differs from tissue to tissue (5) and can be modulated by
different agents (6). Among the most powerful inducers of
class I heavy chains and P2m are type I (a and 13) and type II
(y) interferons (IFNs) (6-9).
Despite many similarities in the biological activities oftype
I and type II IFNs, there are sufficient differences to imply
that the intracellular mechanisms by which they exert their
influence may not be identical. They have different cell
surface receptors (10, 11), and each induces the expression of
a unique set of genes in addition to a common set (12-15).
Hence, it is unclear whether the two types of IFNs utilize
similar strategies to alter the levels of class I antigens.
Transcriptional as well as posttranscriptional processes
were proposed to play a role in gene regulation by IFN (16).
Recently, Friedman and Stark (17) identified a conserved
sequence that spans -30 base pairs (bp) in the promoter
regions of several IFN-a-inducible human genes. This se-
quence is involved in transcriptional regulation of the murine
H-2Kb class I gene by IFN-a/f3 and IFN-y in L cells (18). On
the other hand, Yoshie et al. (19) reported that the expression
of a promoterless human class I gene, HLA-B7, transfected
into L cells is regulated by IFN-,B. We show here that
sequences upstream and downstream of the transcription
initiation site are independently involved in IFN-a and IFN-y
regulation of murine class I genes and that the level of
induction controlled by the promoter region constitutes only
a minor portion of the response in L cells. In addition, we
present results suggesting that the response to IFN-y and -a
may have different sequence requirements in the promoter
region.
MATERIALS AND METHODS
DNA Constructs, Enzymes, and Reagents. Class I genes and
their derivatives were subcloned from BALB/c cosmid and
phage X clones (20-22). We thank C.-L. Kuo for providing the
LdCAT and pBRCAT constructs, T. Wong for FeLVLd (23),
and L. Garfinkel for RSVCAT (24). Sequencing was done by
the method of Maxam and Gilbert (25). Recombinant murine
IFN-y (specific activity, 1.3 x 107 units per mg) was supplied
by Genentech (South San Francisco, CA), and recombinant
human IFN-a A/D [a fusion of the 5' end of IFN-a gene A
and the 3' end of IFN-a gene D (26); specific activity, 8 x 107
units per mg] was supplied by Hoffmann-La Roche.
Cells and Tissue Culture. All transfections were performed
as described by the calcium phosphate precipitation tech-
nique (27).
Assays of Chloramphenicol Acetyltransferase (CAT) Activ-
ity. CAT protein extracts were prepared and assayed accord-
ing to Gorman et al. (24); protein concentrations were
determined by Bio-Rad protein assay.
Quantitative Measurements of Cell-Surface Expression of
Transplantation Antigens by RIA. H-2Dd and H-2Ld transfect-
ants were treated with IFN-y (0.2 to 1000 units per ml) for
variable times (12 hr to 4 days), and the levels of H-2d as well
as H-2k antigens were measured by RIA using antigen-
specific monoclonal antibodies. To observe a maximal re-
sponse for both CAT and class I proteins, a 72-hr treatment
with 2 units of IFN-y per ml was sufficient, so a saturating
amount of IFN-y (20-50 units per ml) and a 3-day incubation
was chosen for all experiments. Transfected and endogenous
transplantation antigens were always induced coordinately in
L cells; therefore, it was possible to study factors affecting
IFN induction of transfected transplantation antigens quan-
titatively by standardizing the expression of exogenous H-2d
antigens relative to endogenous H-2k antigens. Quantitative
RIAs were performed as described (27) with saturating
concentrations of antibodies [28-14-8 and/or 30-5-7 (anti-H-
2Ld), 34-5-8 (anti-H-2Dd), and 11.4 (anti-H-2Kk)] and 1251.
labeled protein A.
RNase Protection Assays. The experiments were performed
as described by Melton et al. (28). CellularRNA was isolated
by the method of Chirgwin et al. (29).
Abbreviations: P32m, 82-microglobulin; IFN, interferon; CAT, chlor-
amphenicol acetyltransferase; kb, kilobase(s); RSV, Rous sarcoma
virus; EF, enhancement factor; FeLV, feline leukemia virus.
3380
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Proc. Natl. Acad. Sci. USA 84 (1987) 3381
RESULTS
The Region Upstream of the Transcription Initiation Site Is
Involved in IFN-y Regulation. The L cell line selected for the
initial study of class I gene regulation expresses high levels of
H-2k class I antigens, comparable to C3H spleen cells (data
not shown). When L cells, or class I gene transfectants of L
cells, are treated with IFNs, the level of exogenous and
endogenous class I antigens is enhanced 2.5- to 8-fold
depending on the experiment and the antigen tested. To
establish the role of 5' class I gene sequences in regulation by
IFN, the H-2Dd and H-2Ld promoter regions were linked to
the bacterial gene encoding CAT, transfected into L cells,
and assayed for CAT activity. This allows an indirect
quantitation of the activity of a eukaryotic promoter (24).
The plasmids DdCAT and LdCAT (Fig. LA) were construct-
ed by ligating 4.8-kilobase (kb) HindIII-BamHI fragments
from the H-2Dd and H-2Ldgenes to the CAT gene. The 4.8-kb
DNA fragments contain sequences homologous to the H-2Kd
class I promoter region for which the transcriptional start site
has been mapped (30). This was established by sequencing
0.4 kb of the H-2Dd flanking region (Fig. 1B). The consensus
sequence involved in transcription regulation by IFN-a (17)
is located in the H-2Dd promoter at position -165 to -136.
The DdCAT and LdCAT plasmids were stably transfected
into fibroblast Ltk- cells, which lack the gene encoding
thymidine kinase. Transfectants were cultured for 3 days in
the presence or absence of saturating concentrations of
murine IFN-y. These conditions were chosen on the basis of
titration and time course studies. In cells transfected with the
LdCAT or DdCAT constructs, an average 1.35 increase in
CAT activity was observed in response to IFN-y (Fig. 2).
Although this increase is small, it was highly reproducible;
each CAT construct was tested a minimum of seven times,
A
Ikb
pBRCAT:
B
RSVCAT:
B
p BR322
and rigorous analysis of the results showed that the effect is
statistically significant (see the legend to Fig. 2). By com-
parison, H-2Dd and H-2Ld cell-surface protein expression in
L cells stably transfected with intact H-2Dd and H-2Ld genes
was increased by IFN-y 2.5- to 6-fold (measured by RIA). For
controls, the plasmids pBRCAT, which has no eukaryotic
promoter, and RSVCAT (Fig. 1), which contains a promoter
from RSV (24), were transfected into L cells. The pBRCAT
transfectants did not express detectable CAT protein levels,
whereas RSVCAT transfectants expressed moderate levels
(lower than LdCAT or DdCAT) that were not influenced by
exposure to IFN-y (Fig. 2).
Localization of the IFN-yZResponsive Sequence in the H-2Dd
Promoter. To map the D CAT sequence conferring respon-
siveness to IFN-y more precisely, a set ofpromoter deletions
was constructed (Fig. 2). The deletion junctions were se-
quenced and denoted by numbers corresponding to the
number of bases remaining in the construct upstream from
the transcription start site (Fig. 1B). Individual constructs
were introduced into L cells, and CAT levels were measured
in IFN-y-treated and untreated cells (Fig. 2).
The deletion constructs A-317, A-262, A-236, and A-159 had
approximately the same response to IFN-'y as the intact
4.8-kb fragments in the DdCAT and LdCAT plasmids, sug-
gesting that an IFN-responsive site is present in all of these
constructs. Inspection of the A-159 sequence, from which 6
bp of the IFN-responsive consensus sequence was deleted,
revealed that fusion with pBR322 DNA restored almost
perfectly the missing nucleotides (see Fig. 3). The expression
of the A-122, A-65, and A-56 plasmids was slightly suppressed
by IFN-y, indicating that the integrity ofIFN-sensitive site(s)
has been destroyed in these constructs.
One of the deletion constructs, A-385, was enhanced by
IFN-y approximately twice as much as the DdCAT, LdCAT,
H CAT B
pBR322' RSV CAT B
A/P H
DdCAT or Ld CAT:
B DB3R322 R H nd nr I d SfInnkinn X BH CAT Bll
C TATA
B
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'AGACTCTAGGGTGTGACTTCTGAAGAGAAGAAGGAATAGGAAGGGTGGAGGTTAGGAAACAGTGATT(!GGGCTTGTGGGTCTCTCCTGGTGTCCTGACAGC
A-262 A-236
TTCTGGGTCAGAACTCGGAGTCACC'ACGACAAACTGCGCTCTGTCCGC!AGTACAGGGTTCAGGCAAAGTCTTGGTTGCCAGGCGGTGAGGTCAGGGGTGGG
A 159 A-122
GAAGCCCAGGGCTGGGGATTCCCC'ATCTCCTCAGTTTCACTTCTGCACCTAAC-CTGGGTCARGGTCCTTCTGCCGGGACACTGATGACGCGCTGGCAGGTCT
A-65 A-56 +1 BamHI
CACTATCATTGGGTGGI!GAGATCCCA'GGAGCCAATCAGCGTCGCCGCGGACGCTGGTTATAAAGTCCACGCAACCCGCGGG'ACTCAGAACCACXGATC ;C
mRNA
FIG. 1. (A) DNA constructs used for 5' flanking region analyses. The plasmids are shown linearized at the conserved BamHI restriction
enzyme site. All constructs contain pBR322 sequences and the bacterial structural gene encoding CAT, followed by a simian virus 40
polyadenylylation signal (indicated by hatched bars). The bold lines indicate regions containing eukaryotic promoters. The plasmid RSVCAT
(25) consists of a 2.1-kb fragment ofpBR322 (labeled pBR322'), the CAT gene, and a promoter from the Rous sarcoma virus (RSV). The plasmid
pBRCAT lacks eukaryotic promoter sequences. To construct the plasmids LdCAT and DdCAT, HindIII linkers were added to the BamHI sites
of the 4.8-kb fragments containing H-2Ld and H-2Dd promoter regions, and the fragments were inserted into pBRCAT. Restriction enzyme sites:
B, BamHI; A/P, Acc I/Pvu II junction; H, HindIII; R, EcoRI; X, Xba I; and C, Cla I. (B) DNA sequence of the H-2Dd promoter region. The
nucleotides are numbered relative to the transcription start site (+1). The IFN-responsive consensus sequence, TATA box, and CAAT box are
underlined. The positions of deletion end points are indicated by arrows. The BamHI site used to join the H-2Dd promoter region to the gene
for CAT is indicated.
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FIG. 2. Localization of the IFN-y-sensitive site in the 5' flanking
region of class I genes. The horizontal bars indicate the extent of the
progressively deleted DdCAT promoter region. The set of deletion
constructs was generated by BAL-31 digestion of DdCAT plasmid
linearized at the Xba I site. The DNA was then cleaved at the Cla I
site in pBR322, end-filled, and ligated to close the plasmid. The
deletion constructs are designated by the number of bases remaining
relative to the transcription start site. The stippled bar indicates the
deletion construct with the highest level of induction, the open bars
indicate the deletion constructs that were induced by the same factor
as the intact promoter; and the hatched bars indicate deletion
constructs that were not induced. The enhancement factor (EF) was
calculated as the ratio of the specific CAT activity (CAT activity per
protein concentration) in cells treated with IFN to that in untreated
cells. The basal levels of CAT gene expression varied between
transfectants. Expression of DdCAT and LdCAT was "5- to 10-fold
higher than that of the H-2Dd deletion constructs; the basal (unstim-
ulated) levels ofCAT activity were: '130 units per mg of protein for
DdCAT and LdCAT and "14 units for A-122, the deletion mutant with
the lowest expression (1 unit = 1 nmol ofchloramphenicol acetylated
per hr at 37'C). Individual transfectants were titrated for CAT
activity so that the induction experiments were done with an
appropriate amount of protein to fall within the 5-50%6 acetylated
range. The measurements of induced and uninduced levels of CAT
activity were made in parallel on the complete set of transfectants.
The standard deviation of each estimate is shown. The probability
that the EFs are statistically different from the uninduced state (EF
= 1) is 99.7% for DdCAT, LdCAT, A-317, A-262, A-236, and A-159
constructs. The probability that the EF for A-385 is different from
parental DdCAT is 99.7%. These calculations were derived by
defining the probability of an individual EF as: 1 - confidence level.
A-317, A-262, A-236, or A-159 constructs. Sequence analysis
ofA-385 DNA revealed that the fusion ofthe H-2DdDNA and
the pBR322 DNA fortuitously created sequences that resem-
ble the IFN-a-responsive consensus sequence (Fig. 3).
Therefore, A-385 carries several potentially functional IFN-
sensitive sequences. Alternatively, the phenotype of A-385
could be explained by the existence ofan additional sequence
that confers IFN responsiveness, between -385 and -317.
The activity of such a sequence may be masked in the
parental DdCAT and LdCAT constructs due to down-regu-
latory regions upstream of -385 or because of the higher
basal level of expression ofthe parental constructs relative to
the deletions.
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FIG. 3. Comparison of the consensus sequence involved in
transcription regulation by IFN with the junctional sequence of
deletion constructs. The human consensus sequence (17) is based on
the four human sequences previously compared: HLA-DR, HLA-A3,
an unidentified HLA, and M72, a metallothionein gene. The human/
mouse consensus sequence is based on the sequences above plus five
murine class I sequences: H-2Kb, H-2Ld, Q10, H-2Kd (31), and
H-2Dd. Bold letters indicate nucleotides conserved in eight of nine
genes. The junctions of pBR322 and H-2Dd promoter DNA in the
deletion constructs A-385 and A-159 are shown, with two alignments
of the A-385 sequence junction. The dots indicate bases conserved
between the junctional sequences and the human/mouse consensus
sequence. The 3'-terminal nucleotides of pBR322 are the same in all
of the deletion junctions (ATCG, part of the Cla I site; see for
example A-385) with the exception of A-159, in which deletion/fusion
removed three additional nucleotides, TCG.
To confirm these results by another assay, the experiments
were repeated with transiently transfected NIH 3T3 cells and
Ltk- cells. In both cell lines, the IFN-y response ofthe entire
set of deletion constructs and control plasmids was quanti-
tatively similar to the response in the stably transfected L
cells (data not shown).
To address the possibility that the progressive deletion of
the H_2Dd promoter may have resulted in changes leading to
incorrect transcription initiation, ribonuclease protection
assays were performed (ref. 28; data not shown). RNA
isolated from cells transfected stably with DdCAT, A-385,
and A-159 was initiated properly. Most ofthe A-122 RNA was
also initiated correctly, but in addition -12% of the A-122
RNA used an aberrant transcription initiation site located
within the pBR322 DNA. The levels of IFN-y-induced A-385
and A-159 CAT RNAs were also measured by quantitative
RNase protection experiments. These experiments estab-
lished that the increase in the number of correctly initiated
transcripts correlates with the increase in the CAT protein
activity (%3-fold enhancement for A-385 RNA and c2-fold
for A-159; data not shown).
DNA Sequences Located Downstream from the Start Site of
Transcription Also Contribute to IFN-y Regulation. In L cells
IFN-y enhanced the membrane expression of the transfected
transplantation antigens from 2.5- to 6-fold, but the analysis
of the 5' encoded response has shown that it accounts for
<2-fold increase in expression (<40%o ofthe overall induction
effect). Therefore, it is unlikely that the 5' encoded response
plays an important role in overall regulation in L cells, and we
reasoned that other mechanisms encoded outside of the
promoter must be involved. Therefore, we looked for regu-
latory sequences located 3' to the transcriptional start site by
studying the regulated expression of the H-2Ld gene fused to
a feline leukemia virus (FeLV) promoter (Fig. 4). The
analysis of this construct cannot differentiate between tran-
scriptional and posttranscriptional regulation. The FeLV
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FIG. 4. DNA sequences downstream from the transcription start site contribute to the ability of class I genes to respond to IFN-y. (A) The
structure of DNA constructs lacking class I H-2Ld promoter regions. The coding H-2Ld region is shown as thin lines (introns) or filled bars
(exons). L encodes the leader peptide; al, a2, a3, the three external domains; T, the transmembrane region; and C, the cytoplasmic tail. The
FeLVLd plasmid has been described (28). It contains a FeLV promoter inserted in front of the H-2Ld structural gene, in place of parental H-2Ld
5' flanking region. The FeLV sequence encodes its own TATA box and transcriptional start site and promotes transcription of the H-2Ld gene
in L cells (24). HFS denotes human flanking sequences present in the plasmid. The FeLVCAT subclone, used to demonstrate that the FeLV
promoter is not regulated by IFN, was made by inserting the BamHI fragment carrying the CAT gene (from DdCAT) in place of the H-2Ld
structural gene. The Ldpro- mutant was constructed by excising a 5' flanking -1-kb Sma I fragment containing the H-2Ld TATA, CAAT, and
CAP site and the IFN-responsive consensus sequence from the H-2Ld gene. The downstream Sma I site (designated S) is located 12 nucleotides
downstream from the transcription initiation site. (B) Effect of IFN-y on the expression of FeLVLd and Ldpro- mutants. L cells transfected
with H-2Ld or FeLVLd or Ldpro- mutants were grown in parallel with or without IFN-y, and the levels of H-2 antigens were quantitated by
RIA. The enhancement of the endogenous H-2Kk protein ranged from 3- to 6-fold. The level of transfected H-2Ld protein changed coordinately
with the H-2Kk expression. To compare different H-2Ld transfectants, the data were standardized relative to the internal H-2Kk control (for
which the EF was set at 100%6). The uninduced level of H-2Ld cell-surface expression was the same in FeLVLd as in H-2Ld transfectants, while
Ldpro- transfectants expressed <5% of the H-2Ld control. The results are averages of five experiments. The standard errors are shown.
promoter functions efficiently in L cells and can initiate
transcription of the H-2Ld gene (23). The FeLV promoter is
not regulated by IFN-y because, when fused to the CAT gene
(Fig. 4A) and transfected into L cells, it is expressed at the
same level in IFN-treated and untreated cells (Table 1). The
cell-surface expression of the FeLVLd protein in L cells is
increased by IFN-y (2- to 4-fold), but not to the same extent
as the parental H-2Ld protein (Fig. 4B). Therefore, when the
wild-type promoter is replaced with a nonregulated promot-
er, the ability of class I genes to respond to IFN-y is
diminished but not abolished.
Additional supporting evidence for the existence of IFN-
responsive sites located outside the promoter region came
from the analysis of an H-2Ld promoter-minus construct,
Ldpro-, from which a 1-kb fragment including the IFN-
responsive consensus sequence was removed from the 5'
flanking region (Fig. 4A). When the Ldpro- construct was
transfected into L cells, it was expressed at low levels
detectable only by a sensitive RIA procedure (<5% of the
Table 1. Comparison of the IFN-a and IFN-y responses of
various CAT gene constructs transfected stably into L cells
EF of selected constructs
IFN DdCAT LdCAT A-385 A-159 A-122 FeLVCAT
IFN-y 1.36 1.38 1.62 1.30 0.88 1.05
IFN-a 1.46 1.41 2.17 1.04 0.66 1.07
The EFs are listed for each transfectant. The IFN-y EFs are from
Fig. 2; the IFN-a EFs are based on one series of experiments done
in duplicate.
wild-type levels; data not shown). It is unlikely that its
expression was regulated by a murine promoter located
outside of the integrated Ldpro- construct, but rather by a
low-efficiency promoter within the plasmid, because 10
different clones of Ldpro- transfectants representing inde-
pendent transfection events expressed H-2Ld at the same
low levels (data not shown). When Ldpro- transfectants were
treated with IFN-y, H-2Ld cell-surface expression was in-
creased by a factor comparable to that seen in FeLVLd
transfected cells (2- to 4-fold; Fig. 4B). Thus, it is likely that
in both FeLVLd and Ldpro-, the sequences located down-
stream from the transcriptional start site play a role in
responsiveness to IFN.
IFN-a Responses Are Also Controlled by the 5' and 3'
Regions of Class I Genes. Because of the known differences
in the two types of IFNs (see Introduction), we asked if the
modified class I genes transfected into L cells showed the
same pattern of regulation by IFN-a as by IFN-y. Since
murine IFN-a was not available to us, we did a limited
number of experiments with recombinant human IFN-a,
which is active on murine cells. L cells transfected stably
with DdCAT, LdCAT, A-385, A-122, and FeLVLd plasmids
and with intact H-2Ld and treated with saturating amounts
(800 units per ml) of IFN-a A/D for 3 days showed compa-
rable levels ofenhancement ofCAT and H-2Ld expression as
those treated with IFN-y (Table 1; the IFN-a EF for FeLVLd
was >50% of the EF for H-2Ld).
An important difference was observed between responses
to IFN-y and IFN-a. One of the tested plasmids, A-159,
which is inducible for CAT expression by IFN-y, did not
respond to IFN-a (Table 1). Apparently the presence of the
Immunology: Korber et al.
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IFN--responsive site was not sufficient for A-159 inducibil-
ity by IFN-a.
DISCUSSION
Using deletional analysis of the murine H-2Dd promoter, we
have identified the DNA region necessary for its regulation
by IFN-,y. It contains a -30-bp sequence located at positions
-165 to -136, which is homologous to the human IFN-a-
responsive consensus sequence (17) and is important for IFN
regulation of the H-2Kb promoter (18). This region, which is
designated "IRS" for IFN-responsive sequence, was pro-
posed to have an effect on transcription initiation by poten-
tiating the action of a functional H-2Kb enhancer in IFN-
treated cells (18). Two restriction enzyme fragments having
enhancer properties were previously identified in the H-2KI
5' flanking region (31). The one located between nucleotides
-213 to -165 was designated "A," and the other one,
located between nucleotides -120 to -61, was designated
"B." Israel et al. (18) have shown that in L cells the response
of the H-2Kb promoter to type I (a + /3) IFN requires the
combination of enhancer A and the IRS. Our results with
human recombinant IFN-a in L cell transfectants support this
conclusion. In contrast the experiments with recombinant
murine IFN-y established that the enhancer A sequence can
be deleted from the H-2Dd promoter without loss of IFN-y
inducibility. It is possible that IFN-y regulation may act
through the IRS independently of enhancer regions or that it
may require enhancer B, which is present in all of our
IFN-y-inducible promoter mutants. At present we cannot
distinguish between these two possibilities, but it is apparent
that in L cells IFN-a and -y have different sequence require-
ments for the promoter-dependent response.
We have shown that in L cells the overall induction of the
transfected class I antigens is up to 6-fold, whereas the
promoter-encoded response to IFN accounts for <2-fold
enhancement in transcription initiation. Consistent with this
observation is the finding that expression of the H-2Ld gene
transcribed from nonregulated promoters can still be en-
hanced by 2- to 4-fold. Thus, the two mechanisms, which
appear to act independently of each other on the regions
located 5' and 3' to the transcription initiation site, account
together for the full response of class I genes to IFNs.
The location and identity of the downstream regulatory
regions have not been established. It may be that these
regions are unrelated to the IRS, since no consensus IRS
sequence was detected in H-2Kd, H-2Dd, and H-2Ld in a
computer search. The 3' regulatory sequences could be
involved in posttranslational events such as an increase in
RNA stability (16) or in the rate of the class I mRNA
translation. Alternatively, the IFN-mediated increase of
FeLVLd and Ldpro- class I proteins could be explained by
the changes in the relative concentrations of 832m and H-2Ld
chains. If P32m is necessary for the transport of class I proteins
to the cell surface and it is present in excess in IFN-treated
cells, then the cell-surface expression of transplantation
antigens may be more efficient in those cells. We consider
this possibility unlikely because FeLVLd has the same
enhancement factor in response to IFN as Ldpro-, which
expresses basal amounts of H-2Ld protein that are lower by
a factor of 20.
The existence of two different regions involved in IFN
responses suggests that the mechanisms operating on them
may be used for the fine tuning of class I gene expression
under different conditions. It would be interesting to define
the relative contribution ofthese two mechanisms in cells and
tissues in which the IFN inducibility and the basal level of
class I antigen expression varies during development or
immune responses. This approach may provide information
about the biological significance ofeach ofthese mechanisms
under physiological conditions.
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